dc.contributor.author |
Sahi, C |
en |
dc.contributor.author |
Knox, JJ |
en |
dc.contributor.author |
Hinder, Victoria |
en |
dc.contributor.author |
Deva, S |
en |
dc.contributor.author |
Cole, D |
en |
dc.contributor.author |
Clemons, M |
en |
dc.contributor.author |
Broom, RJ |
en |
dc.coverage.spatial |
Orlando, FL |
en |
dc.date.accessioned |
2012-04-12T01:31:25Z |
en |
dc.date.issued |
2009-05-20 |
en |
dc.identifier.citation |
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL, 29 May 2009 - 02 Jun 2009. JOURNAL OF CLINICAL ONCOLOGY. ASCO. 27: 2 pages. 20 May 2009 |
en |
dc.identifier.issn |
0732-183X |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/17129 |
en |
dc.description.abstract |
Bone metastases (BM) from renal cell carcinoma (RCC) are common and associated with poor outcomes. While the multi-tyrosine kinase inhibitors (TKI's) sunitinib and sorafenib have advanced the treatment of metastatic RCC, their efficacy on BM is unknown. Urinary N-telopeptide (uNTX) is a marker of bone turnover measured in nmol/mmol creatinine. Elevated uNTX levels correlate with an increased risk of skeletal related events and mortality in patients receiving bisphosphonates for BM from a range of primaries. In this pilot biomarker study we sought to prospectively evaluate the effects on BM of these multi-TKI's in RCC patients. Methods: Eligible patients had advanced RCC, at least one BM evident on imaging and no bisphosphonate exposure within 4 weeks. UNTX levels (OsteoMark) were measured at; baseline and weeks-1, 4, 8 and 12 after commencing either sunitinib or sorafenib. The primary endpoint was the percentage change (Ch) in uNTX levels from baseline. Serum samples were also collected for KIT and VEGFR-2 (Quantikine). Patients also completed pain (including bone pain) and quality of life questionnaires. Results: The uNTX results on the first 9 patients are presented in the table below (7 received sunitinib and 2 sorafenib). In this group, sVEGFR-2 and sKIT levels fell by week-1 and 4 respectively and at week-12 the mean % changes (95% CI) were -34% (-0.53,-0.14) and -38% (-0.58,-0.18). Conclusions: In patients with BM from RCC and at least moderately elevated uNTX levels at baseline, these multi-TKI's show a significant trend to decrease uNTX levels, but perhaps not as effectively as bone-specific therapies (e.g. bisphosphonates) do in other malignancies. SVEGFR-2 and sKIT levels also fell across the patient group over the same period. This pilot data raises questions about the activity of the multi-TKI's in BM from RCC and further research is needed. |
en |
dc.description.uri |
http://www.asco.org/portal/site/ascov2/gsasearch?src=abstracts&return_page=menuitem.a1c60e38cd6d5b9f01ae0094ef37a01d&return_channel=874911ff7fefd110VgnVCM100000ed730ad1RCRD&q=noQstring&search_mode=adv&vmview=abst_meeting_categories_view&the_meeting_ids=65&confID=65&the_title=&ab_auth_last_name=Sahi&the_body=&ab_abstract_no=&x=20&y=6&SelectConference=116&SelectConference=115&SelectConference=111&SelectConference=102&SelectConference=104&SelectConference=103&SelectConference=101&SelectConference=100&SelectConference=74&SelectConference=73&SelectConference=72&SelectConference=70&SelectConference=65&SelectConference=64&SelectConference=63&SelectConference=60&SelectConference=58&SelectConference=55&SelectConference=54&SelectConference=53&SelectConference=52&SelectConference=47&SelectConference=46&SelectConference=45&SelectConference=59%2C57%2C56%2C51%2C50%2C49%2C48%2C44%2C43%2C40%2C42%2C41%2C39%2C38%2C34%2C37%2C36%2C35%2C33%2C26%2C32%2C27%2C23%2C18%2C16%2C15%2C22%2C10%2C19%2C13%2C2%2C6%2C17%2C31%2C30%2C29%2C28 |
en |
dc.publisher |
ASCO |
en |
dc.relation.ispartof |
45th Annual Meeting of the American-Society-of-Clinical-Oncology |
en |
dc.relation.ispartofseries |
JOURNAL OF CLINICAL ONCOLOGY |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Science & Technology |
en |
dc.subject |
Life Sciences & Biomedicine |
en |
dc.subject |
Oncology |
en |
dc.title |
The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma |
en |
dc.type |
Conference Item |
en |
pubs.issue |
15 |
en |
pubs.volume |
27 |
en |
dc.rights.holder |
Copyright: ASCO |
en |
pubs.author-url |
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000276606604184&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e41486220adb198d0efde5a3b153e7d |
en |
pubs.finish-date |
2009-06-02 |
en |
pubs.start-date |
2009-05-29 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Abstract |
en |
pubs.elements-id |
205811 |
en |
pubs.record-created-at-source-date |
2012-04-12 |
en |